Spyglass Pharma is a technology company.
Spyglass Pharma has raised $165.0M across 2 funding rounds.
Spyglass Pharma has raised $165.0M in total across 2 funding rounds.
SpyGlass Pharma is a late-stage biopharmaceutical company specializing in innovative ophthalmic drug delivery technology. Its flagship product is the SpyGlass Pharma™ Drug Delivery Platform, a controlled-release intraocular lens (IOL) system designed to deliver sustained medication—most notably bimatoprost—for up to three years to treat chronic eye conditions such as glaucoma. The platform is implanted during routine cataract surgery, providing a seamless integration into existing surgical workflows and aiming to improve patient adherence and outcomes by eliminating the need for daily eye drops[1][2][3][4].
The company serves ophthalmic surgeons and patients with chronic eye diseases, primarily glaucoma and ocular hypertension, addressing the significant problem of poor adherence to topical therapies and the side effects associated with long-term eye drop use. SpyGlass Pharma has demonstrated positive clinical trial results, including 36-month safety and efficacy data, and is advancing through Phase III studies, reflecting strong growth momentum and potential to transform glaucoma treatment paradigms[1][4][6].
Founded in 2019 by Dr. Malik Y. Kahook and Glenn Sussman, SpyGlass Pharma originated from technology developed at the Sue Anschutz-Rodgers Eye Center at the University of Colorado School of Medicine. The founders identified a critical unmet need for durable, long-acting ophthalmic drug delivery solutions that could overcome the limitations of daily topical medications. Early feasibility studies and Phase II trials showed promising results, validating the concept and enabling the company to secure significant funding to advance clinical development[4][5][6][8].
SpyGlass Pharma is riding the trend toward sustained, long-acting drug delivery systems that improve patient adherence and outcomes in chronic diseases. The timing is critical as the global population ages, increasing the prevalence of cataracts and glaucoma, and as healthcare systems seek more efficient, patient-friendly treatment modalities. The platform’s ability to integrate drug delivery with cataract surgery leverages an existing, high-volume procedure, positioning SpyGlass to influence ophthalmic care standards and reduce reliance on daily topical therapies, which often suffer from poor compliance and side effects[1][3][6].
SpyGlass Pharma is poised to advance its platform through pivotal Phase III trials and regulatory approvals, potentially becoming a standard of care for glaucoma patients undergoing cataract surgery. Future developments include a second-generation system allowing implant removal and replacement, expanding use beyond cataract patients, and broadening drug indications. Trends in personalized medicine and sustained-release therapies will likely shape SpyGlass’s trajectory, enhancing its influence in ophthalmology and chronic disease management. The company’s innovative approach ties back to its mission of transforming eye care by delivering long-term, effective treatment solutions that empower both patients and surgeons[3][4].
Spyglass Pharma has raised $165.0M in total across 2 funding rounds.
Spyglass Pharma's investors include Action Potential Venture Capital, Energy Impact Partners, Jay, QueensBridge Venture Partners, RA Capital, Seventure Partners, Mo El-Bibany, Tim Ferriss.
Spyglass Pharma has raised $165.0M across 2 funding rounds. Most recently, it raised $75.0M Series D in June 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2025 | $75.0M Series D | Action Potential Venture Capital, Energy Impact Partners, Jay, QueensBridge Venture Partners, RA Capital, Seventure Partners, Mo El-Bibany, Tim Ferriss | |
| Jul 1, 2023 | $90.0M Series C | Action Potential Venture Capital, Energy Impact Partners, Jay, QueensBridge Venture Partners, RA Capital, Seventure Partners, Mo El-Bibany, Tim Ferriss |